{"organizations": [], "uuid": "dc054daff0183e9dc7de4c500d27ed492d1deeda", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/02/business-wire-innovus-pharmaceuticals-reports-record-annual-revenue-for-fiscal-2017-of-8-point-8-million-preliminary-q1-2018-revenue-of-4.html", "country": "US", "domain_rank": 767, "title": "Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-04-03T00:05:00.000+03:00", "replies_count": 0, "uuid": "dc054daff0183e9dc7de4c500d27ed492d1deeda"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/02/business-wire-innovus-pharmaceuticals-reports-record-annual-revenue-for-fiscal-2017-of-8-point-8-million-preliminary-q1-2018-revenue-of-4.html", "ord_in_thread": 0, "title": "Innovus Pharmaceuticals Reports Record Annual Revenue for Fiscal 2017 of $8.8 Million, Preliminary Q1 2018 Revenue of $4.3 Million to $4.4 Million and Expects to Exit 2018 Profitable", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "innovus pharmaceuticals, inc.", "sentiment": "none"}, {"name": "innovus pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Year over Year Revenue Increase of 83% with Reduction in Net Loss of 53% in 2017 and Fiscal Year 2018 Net Revenue Annual Run Rate of At Least $18 million\nSAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced full year 2017 net revenue of $8.8 million compared to $4.8 million in revenue for the same period in 2016 and fourth quarter of 2017 net revenue of $2.4 million compared to $1.7 million in revenue for the same period in 2016.\nPreliminary first quarter 2018 net revenue is estimated to be between $4.3 million to $4.4 million or an approximate 85% increase from the fourth quarter of 2017. Innovus Pharma's first quarter 2018 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the consolidated financial statements for the first quarter of 2018.\n“We have seen tremendous growth in our product pipeline and overall net revenue during 2017 and the growth story continues into 2018 with our record first quarter net revenue of an estimated $4.3 million to $4.4 million. We believe our revenue growth into 2018 highlights the continued strength of our ability to sell multiple products through our Beyond Human ® sales and marketing platform and other sales channels,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma. “As we look forward to exiting 2018 as a profitable Company when excluding non-cash expenses, we continue to be focused on increasing annual revenue to at least $18 million by executing on our goals of expanding our product lines and making our products commercially available in the United States and outside of the United States through our partners and new sales channels, as well as achieving profitability.”\nFinancial highlights for the year ended December 31, 2017 included:\nNet revenue totaled $8.8 million for the year ended December 31, 2017 compared to net revenue of $4.8 million for the year ended December 31, 2016 representing an increase of 83.0%. Net revenue during 2017 was impacted by the natural disasters in Florida, Texas as well as major holidays as the Company was unable to advertise its products for a period of time in those regions and periods as a result. These two states generate close to 15% of our total net revenue and have a population of approximately 17 million in our targeted product demographics*. Gross margins increased to 79.0% for the year ended December 31, 2017, compared to 77.5% for the year ended December 31, 2016. Total operating expense increased to $13.9 million and included $1.1 million in non-cash share-based compensation for the year ended December 31, 2017. Net loss totaled $6.5 million, or $0.04 per common share, for the year ended December 31, 2017 compared to a net loss of $13.7 million, or $0.15 per common share, for the year ended December 31, 2016 representing a decrease of 52.5%. The net loss in 2017 included interest expense of $0.9 million, of which $0.8 million was non-cash and related to amortization of debt discounts. The net loss also included a non-cash expense of $0.7 million for the loss on debt extinguishment. Cash balance totaled $1.6 million at December 31, 2017 and current total cash on hand is $4.7 million.\nFinancial highlights for the three months ended December 31, 2017 included:\nNet revenues totaled $2.4 million for the three months ended December 31, 2017 compared to net revenues of $1.7 million for the three months ended December 31, 2016 representing a 40.7% increase. Sequential quarter over quarter revenue increase of 7.1% 2017 compared to a decrease of 10.1% 2016. Gross margins remained consistent at 78.2% for the three months ended December 31, 2017 and 2016. Total operating expenses increased to $3.5 million and included $0.1 million in non-cash share-based compensation for the three months ended December 31, 2017. Loss from operations decreased to $1.1 million during the three months ended December 31, 2017 compared to $1.9 million during the three months ended December 31, 2016 representing a 42.9% decrease. Net loss totaled $1.5 million, or $0.01 per common share, for the three months ended December 31, 2017 compared to $3.4 million, or $0.03 per common share, for the three months ended December 31, 2016 representing a decrease of 55.5%. The net loss in 2017 included a non-cash expense of $0.3 million for the loss on debt extinguishment. The net loss also included interest expense of $0.1 million which was non-cash and related to amortization of debt discounts.\nFourth quarter 2017 and recent developments:\nReceived our first commercial batch of 220,000 units of FlutiCare® in October 2017 and launched FlutiCare® in the U.S. in November 2017; Moved corporate and company operations into a new 17,000 square-foot facility in San Diego, CA in November 2017 that brought in-house the Company’s product fulfillment and inventory storage process. The move was designed to lower product fulfillment costs which will increase our gross product margins and decrease our loss from operations, as well as, provide the necessary office space to accommodate our expected revenue growth in 2018; Received net cash proceeds of $2.7 million from the exercise of warrants to purchase shares of the Company’s common stock, raised net cash proceeds of $1.9 million from the issuance of notes payable during the first quarter of 2018 and current total cash on hand is $4.7 million; Entered into an exclusive license and distribution agreement with Acerus Pharmaceuticals in January 2018 granting them exclusive rights to market and sell UriVarx® in Canada; Entered into an exclusive license and distribution agreement with Lavasta Pharma in January 2018 granting them exclusive rights to market and sell ProstaGorx® in various countries in the Middle East and North Africa; Launched six new products; and Received multiple product approvals in Canada.\nThe Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT today to discuss the financial results and recent business developments. To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international callers. Participant Elite Entry Number: 9576665. A replay of the call will be available for 30 days. To access the replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10118224. The replay will be available shortly after the end of the conference call.\nConsolidated Statements of Operations Three months ended Year ended December 31, December 31, 2017 2016 2017 2016 (unaudited) Net revenue: Product sales, net $2,379,510 $1,691,491 $8,806,300 $4,817,603 License revenue - - 10,000 1,000 Total net revenue 2,379,510 1,691,491 8,816,300 4,818,603 Operating expense: Cost of product sales 519,194 368,810 1,848,325 1,083,094 Research and development 11,829 30,137 38,811 77,804 Sales and marketing 1,983,842 1,363,879 6,853,559 3,621,045 General and administrative 966,928 1,858,215 5,174,827 5,870,572 Total operating expense 3,481,793 3,621,041 13,915,522 10,652,515 Loss from operations (1,102,283 ) (1,929,550 ) (5,099,222 ) (5,833,912 ) Other income and (expense): Interest expense (100,281 ) (660,942 ) (872,166 ) (6,661,694 ) Loss on extinguishment of debt (305,891 ) - (700,060 ) - Other income (expense), net (1,256 ) (190 ) (6,878 ) 1,649 Fair value adjustment for contingent consideration (1,425 ) (1,464,638 ) 194,034 (1,269,857 ) Change in fair value of derivative liabilities 15,542 697,687 (16,596 ) 65,060 Total other expense, net (393,311 ) (1,428,083 ) (1,401,666 ) (7,864,842 ) Loss before provision for income taxes (1,495,594 ) (3,357,633 ) (6,500,888 ) (13,698,754 ) Provision for income taxes - 2,400 3,200 2,400 Net loss $(1,495,594 ) $(3,360,033 ) $(6,504,088 ) $(13,701,154 ) Net loss per share of common stock – basic and diluted: $ (0.01\n)\n$ (0.03\n)\n$ (0.04\n)\n$ (0.15\n)\nWeighted average number of shares of common stock outstanding – basic and diluted 174,575,366\n116,765,431\n157,933,458\n94,106,382\nCondensed Consolidated Balance Sheet Data\nDecember 31, 2017 December 31, 2016 1\n1\nAssets Cash $ 1,564,859 $ 829,933 Accounts receivable, net 68,259 33,575 Prepaid expenses and other current assets 363,080 863,664 Inventories 1,725,698 599,856 Intangible assets and other non-current assets 5,309,010 5,900,350 Total assets $ 9,030,906 $ 8,227,378 Liabilities & Stockholders' Equity Accounts payable & accrued liabilities $ 2,607,121 $ 1,210,050 Total accrued compensation 2,650,197 2,299,593 Deferred revenue and customer deposits 24,690 11,000 Accrued interest payable 3,648 47,782 Short-term loans payable 65,399 - Notes payable and non-convertible debenture, net of discount 1,239,296 681,127 Total derivative liabilities 58,609 483,744 Total contingent consideration 1,479,003 1,685,917 Convertible debentures, net of discount - 714,192 Total stockholders' equity 902,943 1,093,973 Total liabilities & stockholders' equity $ 9,030,906 $ 8,227,378 1 The Condensed Consolidated Balance Sheet Data has been derived from the audited consolidated financial statements as of that date.\nAbout Innovus Pharmaceuticals, Inc.\nHeadquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.\nFor more information, go to www.innovuspharma.com ; www.zestra.com ; www.ejectdelay.com ; www.myvesele.com ; www.urivarx.com ; www.sensumplus.com ; www.myandroferti.com ; www.beyondhumantestosterone.com ; www.getbeyondhuman.com ; www.trybeyondhuman.com ; www.recalmax.com ; www.prostagorx.com ; www.fluticare.com ; www.allervarx.com ; and www.apeaz.com .\n* Population data for Florida and Texas gathered from the 2010 Census Brief from the United States Census Bureau.\nInnovus Pharma’s Forward-Looking Safe Harbor\nStatements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180402005707/en/\nInnovus Pharma Investor Relations\nRandy Berholtz, +1 858-249-7865\nir@innovuspharma.com\nSource: Innovus Pharmaceuticals, Inc.", "external_links": ["http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.prostagorx.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.prostagorx.com&index=12&md5=c7e5fad4714e48eedeef44af5f782007", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.getbeyondhuman.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.getbeyondhuman.com&index=9&md5=19bdc3761863d97d4711b8b538a806c7", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.beyondhumantestosterone.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.beyondhumantestosterone.com&index=8&md5=9491048ef1c3d3966931bf8324d8e6af", "https://www.businesswire.com/news/home/20180402005707/en/", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.myvesele.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.myvesele.com&index=4&md5=326e03872092d51144dc605057b7c566", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.zestra.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.zestra.com&index=2&md5=85e2cbc5cfdb9e3764e79f4d2a72514b", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.ejectdelay.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.ejectdelay.com&index=3&md5=7a32d1dd5fb0c3cd0af115156e114eab", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.trybeyondhuman.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.trybeyondhuman.com&index=10&md5=72937ac4e4890afee075a337f9a0a88a", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.recalmax.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.recalmax.com&index=11&md5=ac5ac50d2a962c7e6cd0af55f5eb4356", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.allervarx.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.allervarx.com&index=14&md5=c8efef24bdd3fca1641dc113739c3d9d", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.myandroferti.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.myandroferti.com&index=7&md5=33b54f349d3c9d98d31c20cbb22fde25", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.innovuspharma.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.innovuspharma.com&index=1&md5=7e2096c2411d20e5d313e4810e3c103b", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sensumplus.com%2F&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.sensumplus.com&index=6&md5=12d37635cfdfed8bdb46578fdc700f35", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.fluticare.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.fluticare.com&index=13&md5=6194902a08dbe47ebdc40473224c8bcb", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.apeaz.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.apeaz.com&index=15&md5=1a08f3fccd3b5141bfd6d26eca516372", "http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.urivarx.com&esheet=51781989&newsitemid=20180402005707&lan=en-US&anchor=www.urivarx.com&index=5&md5=196ca62704bbbc858169037a76a44a9f"], "published": "2018-04-03T00:05:00.000+03:00", "crawled": "2018-04-03T01:47:55.025+03:00", "highlightTitle": ""}